NO851793L - Fremgangmaate ved fremstilling av farmasoeytiske preparater. - Google Patents
Fremgangmaate ved fremstilling av farmasoeytiske preparater.Info
- Publication number
- NO851793L NO851793L NO851793A NO851793A NO851793L NO 851793 L NO851793 L NO 851793L NO 851793 A NO851793 A NO 851793A NO 851793 A NO851793 A NO 851793A NO 851793 L NO851793 L NO 851793L
- Authority
- NO
- Norway
- Prior art keywords
- concentration
- ions
- calcium
- carrier
- salts
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
- 239000011575 calcium Substances 0.000 claims description 42
- 206010052428 Wound Diseases 0.000 claims description 28
- 208000027418 Wounds and injury Diseases 0.000 claims description 28
- 150000002500 ions Chemical class 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000005469 granulation Methods 0.000 claims description 13
- 230000003179 granulation Effects 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 10
- 229910001424 calcium ion Inorganic materials 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 210000000170 cell membrane Anatomy 0.000 claims description 7
- 239000002555 ionophore Substances 0.000 claims description 6
- 230000000236 ionophoric effect Effects 0.000 claims description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000000801 calcium channel stimulating agent Substances 0.000 claims description 4
- 230000010221 calcium permeability Effects 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 13
- 239000000499 gel Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- 229910052700 potassium Inorganic materials 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 210000001723 extracellular space Anatomy 0.000 description 7
- 239000008213 purified water Substances 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 206010063560 Excessive granulation tissue Diseases 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 210000001126 granulation tissue Anatomy 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- ZFLWDHHVRRZMEI-UHFFFAOYSA-N methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C([N+]([O-])=O)C1C1=CC=CC=C1C(F)(F)F ZFLWDHHVRRZMEI-UHFFFAOYSA-N 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- VAZSKTXWXKYQJF-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)OOS([O-])=O VAZSKTXWXKYQJF-UHFFFAOYSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940089027 kcl-40 Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3416777A DE3416777C2 (de) | 1984-05-07 | 1984-05-07 | Pharmazeutische topische Zubereitungen |
| DE19843435113 DE3435113A1 (de) | 1984-05-07 | 1984-09-25 | Pharmazeutische topische zubereitungen zur foerderung der wundgranulation und epithelisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO851793L true NO851793L (no) | 1985-11-08 |
Family
ID=25820959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO851793A NO851793L (no) | 1984-05-07 | 1985-05-06 | Fremgangmaate ved fremstilling av farmasoeytiske preparater. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0165430B1 (fi) |
| AU (1) | AU570558B2 (fi) |
| CA (1) | CA1258231A (fi) |
| CS (1) | CS257788B2 (fi) |
| DD (1) | DD232819A5 (fi) |
| DE (2) | DE3435113A1 (fi) |
| DK (1) | DK201785A (fi) |
| ES (1) | ES8607734A1 (fi) |
| FI (1) | FI81260C (fi) |
| GR (1) | GR851098B (fi) |
| HU (1) | HU196902B (fi) |
| IL (1) | IL74897A (fi) |
| NO (1) | NO851793L (fi) |
| NZ (1) | NZ211994A (fi) |
| PH (1) | PH21464A (fi) |
| YU (1) | YU44497B (fi) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3614095A1 (de) * | 1986-04-25 | 1987-10-29 | Goedecke Ag | Oxyalkylcellulose enthaltende gelzubereitung |
| FR2725901B1 (fr) * | 1994-10-25 | 1997-06-27 | Thorel Jean Noel | Utilisation du calcium en cosmetologie dans le traitement local des phenomenes irritatifs |
| FR2726187A1 (fr) * | 1994-10-26 | 1996-05-03 | Jean Noel Thorel | Utilisation du calcium par voie topique dans le traitement local des dermatoses hyperproliferatives comme le psoriasis |
| DE4439662C2 (de) * | 1994-11-07 | 1997-10-02 | Max Planck Gesellschaft | Verfahren zur Aktivitätsbestimmung von Phosphotyrosinphosphatasen und zur Identifizierung von Effektoren davon |
| DE4447586C2 (de) * | 1994-11-07 | 1998-12-24 | Max Planck Gesellschaft | Verwendung von Ionophoren als Effektoren von PTPasen |
| WO1996019228A1 (en) * | 1994-12-21 | 1996-06-27 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
| US7404967B2 (en) | 1994-12-21 | 2008-07-29 | Cosmederm, Inc. | Topical product formulations containing strontium for reducing skin irritation |
| WO2000009176A1 (en) * | 1998-08-11 | 2000-02-24 | Susanna Elizabeth Chalmers | A wound treatment composition and a wound dressing containing it |
| DE102007002073A1 (de) | 2007-01-09 | 2008-07-10 | Matthias Habenicht | Mittel zur Pflege und antimikrobiellen Behandlung der Haut |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2725261C2 (de) * | 1977-06-03 | 1986-10-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Transparentes Flüssigkeitsverbandmaterial, seine Herstellung und Verwendung |
-
1984
- 1984-09-25 DE DE19843435113 patent/DE3435113A1/de not_active Withdrawn
-
1985
- 1985-04-15 IL IL74897A patent/IL74897A/xx unknown
- 1985-05-02 PH PH32222A patent/PH21464A/en unknown
- 1985-05-03 FI FI851754A patent/FI81260C/fi not_active IP Right Cessation
- 1985-05-03 CA CA000480688A patent/CA1258231A/en not_active Expired
- 1985-05-05 CS CS853235A patent/CS257788B2/cs unknown
- 1985-05-06 NZ NZ211994A patent/NZ211994A/en unknown
- 1985-05-06 ES ES542846A patent/ES8607734A1/es not_active Expired
- 1985-05-06 HU HU851703A patent/HU196902B/hu not_active IP Right Cessation
- 1985-05-06 YU YU746/85A patent/YU44497B/xx unknown
- 1985-05-06 DD DD85276046A patent/DD232819A5/de not_active IP Right Cessation
- 1985-05-06 DK DK201785A patent/DK201785A/da not_active Application Discontinuation
- 1985-05-06 NO NO851793A patent/NO851793L/no unknown
- 1985-05-07 AU AU42041/85A patent/AU570558B2/en not_active Ceased
- 1985-05-07 GR GR851098A patent/GR851098B/el unknown
- 1985-05-07 DE DE8585105587T patent/DE3569197D1/de not_active Expired
- 1985-05-07 EP EP85105587A patent/EP0165430B1/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DK201785D0 (da) | 1985-05-06 |
| CS257788B2 (en) | 1988-06-15 |
| NZ211994A (en) | 1988-04-29 |
| EP0165430B1 (de) | 1989-04-05 |
| EP0165430A1 (de) | 1985-12-27 |
| FI851754A0 (fi) | 1985-05-03 |
| CA1258231A (en) | 1989-08-08 |
| AU570558B2 (en) | 1988-03-17 |
| CS323585A2 (en) | 1987-09-17 |
| AU4204185A (en) | 1985-11-14 |
| PH21464A (en) | 1987-10-28 |
| YU74685A (en) | 1988-10-31 |
| HUT38247A (en) | 1986-05-28 |
| ES8607734A1 (es) | 1986-06-01 |
| DD232819A5 (de) | 1986-02-12 |
| ES542846A0 (es) | 1986-06-01 |
| GR851098B (fi) | 1985-11-25 |
| FI81260B (fi) | 1990-06-29 |
| YU44497B (en) | 1990-08-31 |
| HU196902B (en) | 1989-02-28 |
| FI81260C (fi) | 1990-10-10 |
| IL74897A0 (en) | 1985-07-31 |
| DK201785A (da) | 1985-11-08 |
| IL74897A (en) | 1989-09-10 |
| DE3435113A1 (de) | 1986-04-03 |
| DE3569197D1 (en) | 1989-05-11 |
| FI851754L (fi) | 1985-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2161820A1 (de) | Verfahren zur Lagerung von biologischen Substanzen | |
| Kantaria et al. | Gelatin-stabilised microemulsion-based organogels: rheology and application in iontophoretic transdermal drug delivery | |
| US5739286A (en) | Bone augmentation material | |
| NO851793L (no) | Fremgangmaate ved fremstilling av farmasoeytiske preparater. | |
| CN102743796A (zh) | 用聚乙烯醇制成的丝素蛋白多孔支架及其制备方法和用途 | |
| WO1990014110A1 (en) | Improvements in or relating to pharmaceutical preparations | |
| Lindell et al. | Influence of a charged phospholipid on the release pattern of timolol maleate from cubic liquid crystalline phases | |
| CN106309150A (zh) | 一种医用胶原蛋白敷料及其制备方法和应用 | |
| US20230303807A1 (en) | Cellulose composition | |
| DE3416777C2 (de) | Pharmazeutische topische Zubereitungen | |
| CN115737506B (zh) | 一种含有胶原蛋白的面膜及其制备方法 | |
| CN105106106B (zh) | 一种王不留行黄酮苷软膏剂的制备方法 | |
| Olaisen et al. | Interactions of membrane stabilizing drugs affecting human erythrocytes in vitro | |
| AU2002310785B2 (en) | Porous sponge-like cellulosic material for treatment of injuries | |
| Sato et al. | Glucose metabolism of the isolated eccrine sweat gland. I. The effects of mecholyl, epinephrine and ouabain. | |
| NO317628B1 (no) | Iontoforetisk avlevering av en antimigrenemedisin | |
| CN112472867A (zh) | 一种抗菌医用水凝胶敷料及其制备方法 | |
| JPS62231667A (ja) | 柔軟なアルギン酸カルシウムフイルムの製造方法 | |
| CN111481659A (zh) | Ⅱ型胶原和透明质酸复合凝胶液及制备方法和用途 | |
| Shinde et al. | Flexibilized gelatin film-based artificial skin model: II. Release kinetics of incorporated bioactive molecules | |
| CN212348358U (zh) | 一种高粘度玻璃酸钠类产品生产装置 | |
| CN117462422A (zh) | 一种使用复配交联剂的无定型水凝胶面膜的制备方法 | |
| EP0019167A2 (de) | Arzneipräparat zur Behandlung von Carcinomen und Verfahren zu dessen Herstellung | |
| Jain et al. | PVA/guanidinium oleate transdermal patch as a pH-responsive drug delivery system for the localized and targeted delivery of anticancer drugs | |
| Kempski et al. | Volume and metabolism of C-6 glioma cells suspended in hypotonic medium: An in-vitro model to study cytotoxic brain edema |